iShares Biotechnology ETF (NASDAQ:IBB) Reaches New 1-Year High at $148.60

iShares Biotechnology ETF (NASDAQ:IBB)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $148.60 and last traded at $146.54, with a volume of 697885 shares changing hands. The stock had previously closed at $147.93.

iShares Biotechnology ETF Price Performance

The stock has a 50-day moving average price of $137.50 and a 200 day moving average price of $135.59.

Institutional Trading of iShares Biotechnology ETF

Institutional investors have recently made changes to their positions in the company. Future Financial Wealth Managment LLC acquired a new stake in shares of iShares Biotechnology ETF in the first quarter worth approximately $27,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF during the second quarter worth $31,000. Pacifica Partners Inc. boosted its stake in iShares Biotechnology ETF by 118.2% during the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Crewe Advisors LLC boosted its stake in iShares Biotechnology ETF by 42.9% during the fourth quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after buying an additional 78 shares during the last quarter. Finally, YHB Investment Advisors Inc. acquired a new position in iShares Biotechnology ETF during the first quarter worth $37,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.